News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
FDA
Boston Scientific Corporation Gets Conditional OK for Liberte Stent
March 19, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO (Reuters) - Medical device maker Boston Scientific Corp (BSX.N: Quote, Profile, Research) said on Tuesday its newest drug-eluting stent, the Taxus Liberte system, has received conditional approval from U.S. regulators.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
MORE ON THIS TOPIC
Approvals
Moderna, Merck, UroGen, Score RSV and Cancer Nods in June
June 30, 2025
·
9 min read
·
Tristan Manalac
Vaccines
ACIP Skips Votes on COVID and Moderna’s mRESVIA but Scrutinzes mRNA Vaccine Safety
June 27, 2025
·
2 min read
·
Jef Akst
Neurodegenerative disease
Edgewise Takes a Hit as FDA Blocks Accelerated Path for Becker Muscular Dystrophy Drug
June 27, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
·
4 min read
·
Annalee Armstrong
